about
Rothia aeria as a cause of sepsis in a native jointGenetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis.Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.Systematic review of the prevalence of gout and hyperuricaemia in Australia.Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA).Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities.Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis.Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis.ERAP1 biology and assessment in Ankylosing Spondylitis.Appropriateness of antineutrophil cytoplasmic antibody testing in a tertiary hospital.Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009.Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis.Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitisGenetics of ankylosing spondylitisVenous thromboembolism in medical inpatients--the silent epidemic of neglectTime to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referralsAdverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trialsPredictors of Success in Gout TreatmentAuthor replyThe effect of reducing systemic inflammation on serum urateThe COVID-19 Global Rheumatology Alliance: collecting data in a pandemicBiologic therapy for uveitis: addressing access issues is paramountManagement of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in AustraliaBaseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliancePatients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'ClinicCharacteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
P50
Q33963586-6B0A0945-6576-40AD-84D4-41C7287B20E1Q34996471-CB1C1209-20F9-4F1F-829E-7383A8680728Q35645174-C6045C8E-60D5-4397-ABD6-BDDC8F05077BQ38135856-8361595C-0F68-4700-9D6B-BAA66281D01CQ38199786-8D72ADDA-5700-4A73-8B48-454080E37C06Q38216302-C0AE51B3-C62D-4286-AE75-0977C3CECE0CQ38240821-1B2F0B03-2539-4341-A533-0533EC0A57F7Q41652119-32CC69A8-2FD4-4643-BF9A-F29C4FF4398BQ42608704-000EBC6C-57FB-4101-B2F2-30DE219B75C5Q44298133-E36AA978-D92E-48AD-AB6E-569143F40218Q44356646-F5785F25-5E0A-4070-9505-197658F78CC5Q45813539-E6356EAF-84F1-4928-82A7-C0722CF46B9FQ57667207-81AFFCA2-A092-4056-83E2-91065779B883Q57667313-3FBD3758-39AA-4BE9-877D-E8083155D734Q57786234-54B559FE-6949-443C-8F4C-6D990E0FEEC9Q84680134-4F3C0BA0-5EAC-40B6-9494-FF383927B823Q89699735-ADEB3FD5-634A-4E76-9D99-496A810DDDE0Q89960311-DA43BD52-5FA0-4A87-8CC7-9A751F8A4DC7Q90102848-A756531A-F4CC-4411-B8F2-928D9FD7327DQ90391345-3374C2B4-EC4D-4E09-9595-D50E5F0CB237Q91522956-1F312467-EAE2-469D-9BB1-3C9AB9AB5A11Q91750383-A2C9D43D-04C5-4235-9FA4-17C87183B698Q92447800-7F4CFAB2-E3B8-49F8-9E52-E9AB8D663AD7Q94547563-AF589082-BCF5-4C4E-BD4B-7E0400AD85C8Q94571241-044E923F-324E-4B5D-A2A7-9D7512E62AE4Q96018710-655B89AC-6750-4349-9724-618B79544D25Q96022237-45B8C271-8854-46BD-827E-7D98679FC1EF
P50
description
researcher ORCID ID = 0000-0002-3156-3418
@en
wetenschapper
@nl
name
Philip C Robinson
@ast
Philip C Robinson
@en
Philip C Robinson
@nl
type
label
Philip C Robinson
@ast
Philip C Robinson
@en
Philip C Robinson
@nl
prefLabel
Philip C Robinson
@ast
Philip C Robinson
@en
Philip C Robinson
@nl
P106
P31
P496
0000-0002-3156-3418